Method for relieving pain or producing analgesia with n-butanol
Abstract A method for treating a host for inducing relief of pain or anesthesia which comprises administering hydrolyzed epichlorohydrin, magnesium thiosulfate, or a butanol at the site of the painful area. SUMMARY OF THE INVENTION
It has now been found that by administering various agents, such as hydroyzed epichlorohydrin (i.e., 1-chloro-2,3-epoxy propane), magnesium thiosulfate, or n-butanol directly to the painful area of a host will relieve the pain or produce analgesia therein.
DESCRIPTION OF THE INVENTION
It is known that the manifestation of pain is observed at the so-called trigger points. To successfully treat such pain, the administration of the compounds of the invention, preferably by injection, is found to control the pain in the immediate area as well as in the entire affected region.
One embodiment of the invention relates to the injection of from 1 to 10 ml of a solution of between 0.1 and 1.5 weight percent hydrolyzed epichlorohydrin at the trigger point or immediate painful area. The epichlorohydrin can be hydrolyzed by heating it in water. These amounts have been found to be advantageous, but can be higher or lower if desired. For example, up to 50 ml of a 0.5 weight percent solution can been used for exceptionally severe cases.
Generally, the pain is relieved in minutes following the injection. If necessary, the injections may be repeated, preferably 1-2 days later. If a stronger pain is present the next day at the site of the injection, this may be the result of an local inflammatory reaction. When this occurs, the pain usually disappears the day after, and the long term results are generally better.
Another approach for relieving pain is based upon the fact that pain generally has either an acid or alkaline pattern. This character is recognized through a relationship with the urinary pH: the acid pain being stronger with a lower pH and being weaker with a higher pH. The alkaline pains is just the opposite.
The acid pain corresponds to an anabolic imbalance with the predominant pathogenic action caused by steroids, while the alkaline pain corresponds to a catabolic action, with the predominant pathogenic action caused by fatty acids.
Many different agents can be used to counteract these imbalances. For the anabolic imbalances which are evidenced by acid pain, the injection of a solution of magnesium thiosulfate is utilized. The amount of this solution includes between about 10 and 50 ml of a water solution containing between about 10 and 50 weight percent magnesium thiosulfate.
For alkaline pain, which indicates a catabolic imbalance, a solution of butanol in water is used. The amount of this solution ranges from 5 to 25 ml of a solution of between about 5 and 10 weight percent butanol in water. Either n-butanol or sec-butanol can be used, with n-butanol preferred for best results. It is preferable to add to the butanol solutions about 25 to 50 percent by weight (based on the amount of butanol) of coramine (niketamide) for even better results.
As with the hydrolyzed epichlorohydrin solution, these solutions are preferably administered by injection. If the type of pain cannot be characterized as acid or alkaline, then the epichlorohydrin solution should be administered. It is also possible to use mixtures of these solutions.
When the nature of the disease which is causing the pain is known, more special agents, which can treat the disease or the symptoms of the disease, can be added to these solutions. Also, the number of injections can be repeated to enhance the pain reducing effect.
The preparations of the invention have practically no toxicity in the doses used.
While it is apparent that the invention herein disclosed is well calculated to fulfill the objects above stated, it will be appreciated that numerous modifications and embodiments may be devised by those skilled in the art, and it is intended that the appended claims cover all such modifications and embodiments as fall within the true spirit and scope of the present invention.
Abstract A method for treating a host for inducing relief of pain or anesthesia which comprises administering hydrolyzed epichlorohydrin, magnesium thiosulfate, or a butanol at the site of the painful area.
TECHNICAL FIELD
This invention relates to methods and preparations for relieving pain or producing analgesia.
BACKGROUND ART
A number of methods exist for treating pain: an example being U.S. Pat. No. 3,898,325. The applicant has found a new method is particularly effective for this purpose in compositions which are relatively simple to prepare and administer.
SUMMARY OF THE INVENTION
It has now been found that by administering various agents, such as hydroyzed epichlorohydrin (i.e., 1-chloro 2,3-epoxy propane), magnesium thiosulfate, or n-butanol directly to the painful area of a host will relieve the pain or produce analgesia therein.
DESCRIPTION OF THE INVENTION
It is known that the manifestation of pain is observed at the so-called trigger points. To successfully treat such pain, the administration of the compounds of the invention, preferably by injection, is found to control the pain in the immediate area as well as in the entire affected region.
One embodiment of the invention relates to the injection of from 1 to 10 ml of a solution of between 0.1 and 1.5 weight percent hydrolyzed epichlorohydrin at the trigger point or immediate painful area. The epichlorohydrin can be hydrolyzed by heating it in water. These amounts have been found to be advantageous, but can be higher or lower if desired. For example, up to 50 ml of a 0.5 weight percent solution can been used for exceptionally severe cases.
Generally, the pain is relieved in minutes following the injection. If necessary, the injections may be repeated, preferably 1-2 days later. If a stronger pain is present the next day at the site of the injection, this may be the result of an local inflammatory reaction. When this occurs, the pain usually disappears the day after, and the long term results are generally better.
Another approach for relieving pain is based upon the fact that pain generally has either an acid or alkaline pattern. This character is recognized through a relationship with the urinary pH: the acid pain being stronger with a lower pH and being weaker with a higher pH. The alkaline pains is just the opposite.
The acid pain corresponds to an anabolic imbalance with the predominant pathogenic action caused by steroids, while the alkaline pain corresponds to a catabolic action, with the predominant pathogenic action caused by fatty acids.
Many different agents can be used to counteract these imbalances. For the anabolic imbalances which are evidenced by acid pain, the injection of a solution of magnesium thiosulfate is utilized. The amount of this solution includes between about 10 and 50 ml of a water solution containing between about 10 and 50 weight percent magnesium thiosulfate.
For alkaline pain, which indicates a catabolic imbalance, a solution of butanol in water is used. The amount of this solution ranges from 5 to 25 ml of a solution of between about 5 and 10 weight percent butanol in water. Either n-butanol or sec-butanol can be used, with n-butanol preferred for best results. It is preferable to add to the butanol solutions about 25 to 50 percent by weight (based on the amount of butanol) of coramine (niketamide) for even better results.
As with the hydrolyzed epichlorohydrin solution, these solutions are preferably administered by injection. If the type of pain cannot be characterized as acid or alkaline, then the epichlorohydrin solution should be administered. It is also possible to use mixtures of these solutions.
When the nature of the disease which is causing the pain is known, more special agents, which can treat the disease or the symptoms of the disease, can be added to these solutions. Also, the number of injections can be repeated to enhance the pain reducing effect.
The preparations of the invention have practically no toxicity in the doses used.
While it is apparent that the invention herein disclosed is well calculated to fulfill the objects above stated, it will be appreciated that numerous modifications and embodiments may be devised by those skilled in the art, and it is intended that the appended claims cover all such modifications and embodiments as fall within the true spirit and scope of the present invention.
REVICI is named after its inventor Dr.Emanual Revici of USA. * n-Butanol exerts an increased muscular contraction on the muscular walls of the bleeding vessels and thus brings about stoppage of the acute haemorrhage. n-Butanol inhibits enzymes like proteolytic enzyme present in plasmin and delays retraction of blood clots. In addition it acidifys the site of damage, thereby preventing the condition of alkalosis. Alkalosis of the blood vessels causes excessive bleeding and pain. Hence, Revici also acts as an analgesic. * Citric Acid, which is a rich source of Vitamin-C, helps in capillary integrity and increases resistance to haemorrhage.Since revici is in injectable form, it reaches unchanged to the site of action. It is metabolised mainly in the liver by enzyme dehydroxygenase. The metabolites do not have any harmful action and are excreted in urine.
SAFETY OF REVICI
REVICI injection has the highest safety margin because of higher therapeutic index (75-100) Hence, very high dosages as & when required can be given to achieve the result.
Therapeutic index is the ratio between LD50 & ED50.
LD50: Lethal dose - a dose at which alteast 50 % of the selected group die. ED50: Effective dose - a dose at which alteast 50 % of the selected group shows the effect of the drug.
INDICATIONS o External & internal haemorrhages o All surgical procedures o Dentistry o Pre & post operative haemorrhages o Obstetrics & Gynaecology -> Metrorrhagia -> Dysfunctional uterine bleeding -> Post-partum haemorrhage -> Haemorrhage associated with IUCD.
DOSAGE 1 ampoule of 5 ml 3 times daily or as & when required.
CONTRAINDICATIONS No contraindications are known so far but it should be used with caution in patients with severe hepatic dysfunction.
-------------------- pingpong Posts: 361 | From At the Pingpong Tournament | Registered: Oct 2007
| IP: Logged |
Combined, both the abstracts listed at the link above, and butanol's clinical use mentioned above in the previous post would imply some ancillary role for butanol in an abx regimen for treating lyme.
-------------------- pingpong Posts: 361 | From At the Pingpong Tournament | Registered: Oct 2007
| IP: Logged |
bettyg
Unregistered
posted
pingpong, thank you for your recent discovery.
thanks also for breaking it up because all of this medical TECHNICAL TERMS by neuro brain can NOT absorb at all.
so i can't comment on it; way above my head on this one but bringing it up!
IP: Logged |
treepatrol
Honored Contributor (10K+ posts)
Member # 4117
posted
For the anabolic imbalances which are evidenced by acid pain, the injection of a solution of magnesium thiosulfate is utilized.
Wile i haven't used it, I noticed its use in lab research on borrelial for isolation of Bb antigens.
United States Patent 6,248,368 Valletta June 19, 2001
-------------------------------------------------------------------------------- Use of magnesium based products for the treatment or prophylaxis of autoimmune diseases
Abstract Pharmaceutically acceptable compositions suitable for releasing magnesium ions to an organism, such as organic or inorganic magnesium salts or complexes thereof, are used to prevent and to treat neoplastic and autoimmune diseases, whose origin can be attributed to magnesium depletion. For the new therapeutic indications the magnesium based product, preferably magnesium pyrophosphate, is usually administered orally or parenterally, preferably in association with vitamin B.sub.6.
Maybe its the Magnesium???
-------------------- Do unto others as you would have them do unto you. Remember Iam not a Doctor Just someone struggling like you with Tick Borne Diseases.
The Lyme Disease Network is a non-profit organization funded by individual donations. If you would like to support the Network and the LymeNet system of Web services, please send your donations to:
The
Lyme Disease Network of New Jersey 907 Pebble Creek Court,
Pennington,
NJ08534USA http://www.lymenet.org/
UBBFriend: Email this page to someone!
![[group hug]](graemlins/grouphug.gif)
![[kiss]](graemlins/kissing.gif)
Printer-friendly view of this topic